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Abstract
Background: Restricted use of third-generation cephalosporins and fluoroquinolones has been linked to a reduced
incidence of hospital-acquired infections with multidrug-resistant bacteria. We implemented an intensified antibiotic
stewardship (ABS) programme in the medical service of a university hospital center aiming at a reduction by at least
30% in the use of these two drug classes.
Methods: The ABS programme was focused on the 300-bed medical service. Prescription of third-generation
cephalosporins was discouraged, whereas the use of penicillins was encouraged. Monthly drug use density was
measured in WHO-ATC defined and locally recommended daily doses (DDD and RDD) per 100 patient days, to
evaluate trends before (01/2008 to 10/2011) and after starting the intervention (1/2012 to 3/2013). The effect was
analysed using interrupted time-series analysis with six non-intervention departments as controls.
Results: Following initiation of the ABS intervention, overall antibiotic use in the medical service declined (p < 0.001).
There was a significant intervention-related decrease in the use of cephalosporins and fluoroquinolones (p < 0.001)
outperforming the decreasing baseline trend. Trend changes observed in some of the control departments were
smaller, and the difference between trend changes in the medical service and those in control departments were
highly significant for overall use and cephalosporin use reductions (p < 0.001) as well as for the increasing use of
penicillins (p < 0.001). Mean use density levels (in RDD per 100 patient days) dropped for cephalosporins from 16.3
to 10.3 (−37%) and for fluoroquinolones from 17.7 to 10.1 (−43%), respectively. During the same period, the use of
penicillins increased (15.4 to 18.2; 18%). The changes in expenditures for antibiotics in the medical service compared to
control services minus programme costs indicated initial net cost savings likely to be associated with the programme.
Conclusion: An intensified ABS programme targeting cephalosporin und fluoroquinolone use in the setting of a large
academic hospital is feasible and effective. The intervention may serve as a model for other services and hospitals with
a similar structure and baseline situation.
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Background
The steady increase in antimicrobial drug resistance is of
growing concern. Strategies to reduce antimicrobial
resistance essentially include limiting the inadequate use
of antibiotics in both the hospital and primary care
settings [1,2]. Earlier studies have shown that the reduced
prescribing of aminoglycosides in hospitals may be associ-
ated with a reduction in the incidence of aminoglycoside-
resistant gram-negative bacteria [3,4]. Recent observations
show that reduced prescribing of particular other anti-
bacterial drug classes, notably third-generation cepha-
losporins [5,6] and fluoroquinolones (FQ) [6,7], may
reduce the incidence of hospital-acquired C. difficile [8-11],
methicillin-resistant Staphylococcus aureus (MRSA) [12-14]
and gram-negative bacteria producing extended-spectrum
betalactamase (ESBL) [15,16].
Reducing the antibacterial drug use density in tertiary
care centers may be challenging [17]. These centers serve
as referral hospitals for patients with difficult to treat con-
ditions and enhanced risk for complications including
healthcare-associated infection that may require aggressive
treatment. Often, such conditions include cancer, trans-
plant or immunodeficiency or patients who are pretreated
and being transferred because of treatment failure. How-
ever, practice guidelines commonly include treatment rec-
ommendations only for initial therapy. Given the limited
evidence for second-line therapies, the often complex
underlying disease and comorbidities of the tertiary care
hospital patients, antimicrobial therapies in tertiary center
patients often need to be individualized and based on ex-
pert consultation. Strategies to address inadequate therapy
in such centers usually require an intensive infectious dis-
ease consultation service, frequent audits and feedback
[1,18]. Whether relevant reductions in antimicrobial drug
use density levels can be achieved here is uncertain. The
tendency in many acute care hospitals is an increase in
antimicrobial drug use density rather than a decrease
[19,20] which in part is explained by decreasing lengths of
stay and in part by an ever increasing number of patients
with more complex diseases.
Freiburg University Hospital is a 1600-bed academic
teaching hospital and tertiary care referral center with
all major services and departments including renal, lung,
heart and hematopoetic stem cell transplant centers.
Locally consented infection management guidelines for
the most frequent indications were first available in writ-
ten form in 2006. In the following years, the overall anti-
biotic use density remained relatively stable. The use of
fluoroquinolones increased slightly in the following years,
in part due to the adoption of fluoroquinolone prophylaxis
in neutropenia patients. The use of penicillins did not
increase, the proportion of prescribed doses of penicillins
within the betalactam class remained well below 50%, and
ceftriaxone became one of the most prevalent antibacterial
drugs. In 2010, we observed slightly increasing rates of
enteric bacteria producing extended-spectrum betalac-
tamases (ESBL) and vancomycin-resistant enterococci
(VRE).
Methods
Setting and antibiotic stewardship programme
Freiburg University Hospital is a 1600-bed academic
teaching hospital and tertiary care referral center with
all major services and departments including renal, lung,
heart and hematopoetic stem cell transplant centers.
Locally consented infection management guidelines for
the most frequent indications were first available in
written form in 2006. In the following years, the overall
antibiotic use density remained relatively stable. The
use of fluoroquinolones increased slightly in the following
years, in part due to the adoption of fluoroquinolone
prophylaxis in neutropenia patients. The use of penicillins
did not increase, the proportion of prescribed doses of
penicillins within the betalactam class remained well
below 50%, and ceftriaxone became one of the most
prevalent antibacterial drugs. In 2010, we observed slightly
increasing rates of enteric bacteria producing extended-
spectrum betalactamase (ESBL) and vancomycin-resistant
enterococci (VRE).
In 2011, we revised our internal guidelines and recom-
mended penicillins as first-line drugs for many thera-
peutic indications while empirical cephalosporin and
fluoroquinolone use were explicitly discouraged (“use
more pens than cephs”, “don’t use combination therapy
with FQs”, “abandon FQ prophylaxis in hematology-
oncology”). The revised guidelines where consented, dis-
cussed in educational conferences and published in the
intranet between July and October 2011. An intensified
programme focusing on the 300-bed medical service was
initiated to ensure compliance with the new guidelines
and to achieve an at least 30% reduction in the prescrib-
ing of cephalosporins and fluoroquinolone within one
year. This target of 30% was primarily derived from a
benchmark analysis of tertiary care hospital antibiotic
use data available through a surveillance and internal
quality assurance programme (www.antiinfektiva-surveil-
lance.de). The focus on the medical service was due to
the facts that the medical service predominantly used
third-generation cephalosporins and that >50% of all
doses of third-generation cephalosporins and fluoroqui-
nolones prescribed hospital-wide were in the medical
service. We used the surgical service (including divisions
of general surgery, thoracic, cardiac and vascular surgery,
transplant surgery, and surgical critical care), urology,
orthopedic surgery, neurology, neurosurgery, and the
ENT department (all in total 750 beds) as controls. In the
control departments no intensified ABS intervention took
place.
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The programme included four components: guideline
revision, information and education, regular ward rounds
and intensified infectious disease consultations, and feed-
back. Briefly, local clinical guidelines and pathways were
revised by a multidisciplinary team including infectious
disease physicians, clinicians from various divisions in-
cluding hematology, emergency and intensive care medi-
cine and general medicine, and clinical pharmacists.
Guidelines discouraged the use of cephalosporins and
fluoroquinolones, discouraged combination therapy, and
encouraged the use of penicillins. The guidelines were
made available in written pocket-like formats and were
easily accessible through the hospital intranet. Educational
events included initial short division-specific team brief-
ings, summarizing the revised guidelines and explaining
the overall strategy. We provided prospective audit with
intervention and feedback in form of weekly rounds on
“high antiinfective consumer wards” like the medical
intensive care units and hematology units. The rounds
focused on the appropriate choice of the drugs for
empirical and targeted therapy, on dosing, and on early
deescalation. In addition, quartely antibiotic use data per
ward, service and division specifying trends in cephalo-
sporin and fluoroquinolone versus broad-spectrum peni-
cillin use were made available in the intranet to members
of the infection management and control committee.
Finally, the infectious disease service increased the num-
ber of bedside consultations in the medical service with
academic detailing, individualized written recommenda-
tions, and follow-up consultations to enhance guideline
adherence and compliance with the recommendations.
Outcome data
Monthly antibiotic use data were obtained from the hos-
pital pharmacy and were expressed as WHO-ATC de-
fined daily doses (DDD) and dose definitions adapted to
local guidelines to account for discrepancies between
DDD for penicillins and commonly and locally recom-
mended daily doses in hospital practice (recommended
daily doses [RDD]) normalized per 100 patient (occupied
bed) days. The data were administered using Microsoft®
Access software and available on ward, division and service
level and further aggregated as appropriate. Data on actual
drug expenditures were also retrieved from the pharmacy
database. No attempt was made to adjust for inflation.
Programme cost data were estimated based on time sheets
for personnel involved in the programme (senior physician,
infectious disease fellow, pharmacist, data manager). The
DRG case mix index, data on length of stay and on hospital
deaths were obtained from the administration.
Statistical analysis
The effect of the intervention on drug use density was
analysed using interrupted time-series analysis for the
periods between 1/2008 through 11/2011 as pre-interven-
tion, and between 1/2012 through 3/2013 as post-interven-
tion period. Basically, interrupted time-series analysis
allows accounting for two effects of the intervention: a
level-effect or a slope-effect. As our data indicate a
change in the slope rather than a level change, our
regression model to analyse the use of antibiotic Y over
time t in a single setting was specified accordingly:
Y t ¼ β0 þ β1  timet þ β2  time after interventiont
þ ut
In detail, β0 determines the baseline level of the re-
spective antibiotic use in January 2008, β1 determines
the overall linear trend in the use of the respective anti-
biotic over the entire study period. β2 determines the
change in post intervention trend where time after inter-
vention is a continuous variable indicating the number
of months after the start of the intervention and is coded
as zero before the intervention. ut represents the error
term.
We applied the same interrupted time-series approach
for the control departments and compared the post-
intervention trend changes (β2) in the medical service
with the average effect (β2) in the control departments.
All analyses were carried out using Stata 12 (StataCorp,
College Station, TX, USA). We applied linear regressions
with Newey-West standard errors with a maximum lag
of 2 to be considered in the autocorrelation structure.
Stata’s lincom command was applied to subtract the
average β2 in the non-intervention settings from the
β2 in the medical service.
Descriptive statistical analysis was performed by using
Microsoft Excel® Software. Heteroskedastic t-test was ap-
plied to compare mean drug use densities before and after
the intervention. Mann–Whitney U test was used to com-
pare drug expenditures before and after the programme.
Results
Following the initiation of the intensified ABS programme,
the overall antibiotic use density in the medical service
declined by 14-20%. The mean use density values before
and after the intervention were 110.5 versus 94.8 DDD per
100 patient days (−14.2%, P < 0.001) or 86.1 versus 68.8
RDD per 100 patient days (−19.9%, P < 0.001), respectively
(Table 1 and Figure 1). This was explained by a decreasing
use of both cephalosporins (in particular third generation
cephalosporins) and fluoroquinolones. The mean use
density levels for cephalosporins dropped from 16.3 to
10.3 RDD per 100 patient days (−36.8%, P < 0.001), and
for fluoroquinolones the decline was from 17.7 to 10.1
RDD per 100 patient days (−43.2%, P < 0.001), respect-
ively. These trends were similar when they were calcu-
lated in DDD per 100 patient days (−30%, and −39%,
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respectively) (Table 1). During the same period, the
prescription of penicillins increased by 18% (RDD per
100 patient days) to 28% (DDD per 100 patient days)
(Table 1). Monitoring hospital deaths and DRG case-
mix index ensured that changes in the above outcomes
were not related to a change in these variables (data
not shown).
We next analysed trend changes using monthly drug
use levels expressed in RDD per 100 patient days in an
interrupted time-series model. Using the single-level
model, it was shown that the use of cephalosporins
already declined slightly before the intervention (0.0169
RDD per 100 patient days each month), but an add-
itional major decrease in cephalosporin use (0.517 RDD
per 100 patient days each month, P < 0.001) was seen
after the intervention (Table 2 and Figure 2). The trend
changes for fluoroquinolone use post-intervention were
similar and also statistically significant (Table 2 and
Figure 2). The model indicated that penicillin use in-
creased substantially and significantly after the intervention
Table 1 Comparison of mean monthly drug use density values expressed as DDD per 100 patient days or RDD per 100
patient days in the medical service pre- and post-intervention
DDD/100 RDD/100
Drug class Pre- Post- Percent change P value Pre- Post- Percent change P value
Cephalosporins 20.1 14.0 −30.2% <0.001 16.3 10.3 −36.8% <0.001
3° Cephalosporins 14.4 7.4 −49.0% <0.001 13.1 6.4 −51.3% <0.001
1°/2° Cephalosporins 5.6 6.6 +17.7% <0.05 3.2 3.9 +23.6% <0.01
Penicillins 23.1 29.6 +28.3% <0.001 15.4 18.2 +17.9% <0.001
Piperacillin ± BLI 9.3 9.9 +5.8% ns 10.9 11.5 +5.8% ns
Aminopenicillins + BLI 6.6 11.3 +69.9% <0.001 2.4 4.1 +70.4% <0.001
Narrow-spectrum penicillins 7.1 8.5 +19.1% ns 2.1 2.5 +20.3% ns
Carbapenems 9.5 8.3 −12.7% <0.01 6.9 5.8 −15.7% <0.001
Fluoroquinolones 19.6 12.0 −38.5% <0.001 17.7 10.1 −43.2% <0.001
Aminoglycosides 0.9 0.7 −18.9% ns 0.7 0.6 −19.1% ns
Glycopeptides 4.3 3.9 −8.6% ns 4.3 3.9 −8.6% ns
Tetracyclines 1.4 0.9 −36.9% <0.01 1.0 0.7 −35.9% <0.01
Macrolides/clindamycin 18.1 13.7 −24.4% <0.001 10.3 7.9 −22.8% 0.001











Figure 1 Trends in the overall monthly antibiotic use density (expressed as RDD per 100 patient days) in the medical service
pre- and post-intervention.
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(0.34 RDD per 100 patient days per month). Separate ana-
lyses of the data for the medical ICU, hematology-oncology
and other internal medicine wards indicated that the re-
duced fluoroquinolone prescription was primarily related
to trend changes in hematology-oncology, and the reduced
cephalosporin prescription post-intervention was particu-
larly strong in the medical ICU (Table 3).
The multi-level model confirmed the effect of the inter-
vention on the medical service compared with the control
departments (Table 4). Interestingly, there was also some
trend change in some control departments around the time
of the intervention, but it did not reach the magnitude of
the trend change seen in the medical service. The reduction
of cephalosporins (p < 0.001) and overall antibiotic use
(p < 0.001) as well as the increase in penicillin pres-
criptions (p < 0.001) following the intervention remained
significant when compared with the control departments.
As a secondary objective we evaluated potential net sav-
ings associated with the programme (drug expenditures
changes compared to control services minus programme
costs) in a simple before/after analysis. The mean annual
drug expenditures on all antibiotics in the medical service
pre-intervention were 1,038,648 € decreasing to 594,684 €
in the post-intervention period (−43%) while in the control
departments there was also a downward trend which, how-
ever, was much smaller (−24%, 781,440 € pre-intervention,
595,956 € post-intervention), giving a conservative estimate
of at least 248,000 € annual cost reduction (−19% instead
of −43%) in the medical service. The team involved in the
intensified medical service-focussed programme was a se-
nior physician with a dedicated effort to the programme of
35%, an infectious disease fellow (75%), a pharmacist (12%),
and a data manager (6%) corresponding to yearly personnel
costs of 102,950 €. Thus, estimated initial annual net
savings of at least 145,000 € were likely to be associated
with the programme.
Discussion
Interrupted time-series (ITS) analysis is regarded as the
statistic tool of choice to differentiate between baseline
trends and true intervention-related effects of ABS pro-
grammes. In the recently published Cochrane metaanalysis
[18] most of the 86 finally included studies with adequate
quality were designed as ITS analysis, underscoring the
Table 2 Monthly drug use density (expressed as RDD per 100 patient days) trends in the medical service pre- (baseline)
and post-intervention as estimated in a single-level interrupted time-series model (P values in parentheses)
Cephalosporins Fluoroquinolones Penicillins TOTAL
Baseline −0.02 −0.10 −0.03 −0.13
trend β1 (ns) (<0.001) (ns) (0.038)
Post-intervention −0.52 (<0.001) −0.40 (<0.001) +0.34 (<0.001) −1.10 (<0.001)
trend change β2
Intercept β0 16.61 (<0.001) 19.96 (<0.001) 16.11 (<0.001) 88.73 (<0.001)








201020092008 2011 2012 2013
Figure 2 Trends in the monthly antibiotic use density (expressed as RDD per 100 patient days) for cephalosporins (blue).
Fluoroquinolones (red) and penicillins (green) in the medical service pre- and post-intervention.
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importance of this type of evaluation in field of ABS
[18,21]. In fact, we considered it as essential to measure
and evaluate time trends for antibiotic use, both in and
outside the primary target service by ITS analysis to esti-
mate the contribution of our additional efforts optimizing
antimicrobial drug treatment. Of note, a trend of fewer
fluoroquinolone prescriptions was already observed prior
to the programme initiation, and was related to a decision
taken earlier in 2011 to abandon fluoroquinolone prophy-
laxis in hematology-oncology patients [22].
Epidemiological data from Germany [19,23] indicate a
dominance in acute-care hospitals of cephalosporins
over penicillins, and a frequent use of fluoroquinolones.
We were surprised to see that despite considerable
efforts, cephalosporins had remained the dominant
antibacterial drug class in this hospital, at least if RDD ra-
ther than DDD were counted. There is a well-established
association between the use of third generation cephalo-
sporins, fluoroquinolones and the emergence and spread
of multidrug-resistant bacteria and Clostridium difficile at
hospital level [8,22,24,25]. Moreover, it has been shown
that a substantial part of the MRSA related costs could be
prevented if the use of fluoroquinolones and cephalospo-
rins was reduced [5]. Previous studies have demonstrated
significant decreases in cephalosporin and fluoroquinolone
use with various outcomes [6,10,26,27]. Some studies have
not assessed overall drug or drug-class consumption,
other reported a compensatory increase in carbapenem
prescriptions. There still remains the question of feasi-
bility and sustainability of programmes in particular in
Table 3 Monthly drug use density (expressed as RDD per 100 patient days) trends in hematology-oncology (Hem-Onc)
and the medical ICU pre- (baseline) and post-intervention as estimated in a single-level interrupted time-series model;
only trend changes that were statistically significant are shown
Cephalosporins Fluorochinolones Penicillins TOTAL
Baseline trend β1 Hem-Onc −0.05 (ns) −0.18 (<0.001) −0.00 (ns) −0.17 (ns)
Medical ICU −0.045 (ns) −0.02 (ns) −0.49 (<0.001) −0.31 (ns)
Post-intervention Hem-Onc −0.41 (<0.001) −1.16 (<0.001) +0.17 (ns) −2.17 (<0.001)
trend change β2 Medical ICU −1.06 (<0.05) +0.04 (ns) +1.83 (<0.001) −1.11 (ns)
Intercept β0 Hem-Onc 14.06 (<0.001) 38.29 (<0.001) 18.88 (<0.001) 124.1 (<0.001)
Medical ICU 26.87 (<0.001) 13.02 (<0.001) 40.93 (<0.001) 148.3 (<0.001)
N 63 63 63 63
Table 4 Monthly drug use density (expressed as RDD per 100 patient days) trends ß2 in the medical service
post-intervention compared to the effects of a hypothetical intervention at six control services according to regression
analysis (P values in parentheses)
Post-intervention trend changes β2
Service/department Cephalosporins Fluoroquinolones Penicillins TOTAL
Medical service −0.517 −0.40 0.34 −1.102
(intervention) (<0.001) (<0.001) (<0.001) (<0.001)
Department A −0.171 0.01 0.261 0.247
(control) (0.024) (ns) (<0.001) (0.041)
Department B −0.40 0.451 −0.0579 0.0246
(control) (<0.001) (<0.001) (0.1) (ns)
Department C 0.057 −0.315 0.0501 −0.332
(control) (ns) (<0.001) (ns) (0.006)
Department D −0.134 −0.0431 0.0418 −0.272
(control) (0.077) (ns) (ns) (0.024)
Department E −0.278 −0.021 −0.0305 −0.534
(control) (<0.001) (ns) (ns) (<0.001)
Department F −0.426 0.002 0.206 −0.454
(control) (<0.001) (ns) (<0.001) (<0.001)
Medical service −0.292 −0.414 0.261 −0.882
versus controls* (<0.001) (<0.001) (<0.001) (<0.001)
*Stata’s lincom command was applied to simply subtract the average β2 in the control (non-intervention) settings (rows 2–7) from the β2 in the medical service in
which the intervention took place.
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large acute-care hospitals without inducing negative
compensatory side-effects. Tertiary referral hospitals
are often challenging sites for antibiotic stewardship
interventions given the complex patient conditions and
the involvement of various medical specialties with dif-
ferent department structures and internal guidelines.
The present programme essentially addressed and im-
plemented a revised policy of recommending penicillins
as first-line drugs for many therapeutic indications. We
encouraged the preferential use of penicillin, flucloxacillin,
and ampicillin-sulbactam rather than cephalosporins (and/
or fluoroquinolones) for a number of indications. Our re-
sults demonstrate that it is feasible to reduce cephalosporin
and fluoroquinolone use by >30% within 12 months in
the setting of a large tertiary university hospital using a
relatively simple bundle approach. As intended, we ob-
served a significant increase in penicillin prescriptions
whereas the overall antibiotic use showed a decline which
appeared to be attributed to the programme and is a
favourable “side effect”. The use of carbapenems dropped,
despite we report a slightly increasing rate of ESBL isolates
since 2010. This may reflect a more rational use of this
drug class after the intervention, and indicates an overuse
in the pre-intervention period. Similar effects were
observed in the class of tetracyclines and macrolides.
The sustainability of the programme and its effects
need to be determined, and the efficacy of a similar policy
in other services of our hospital needs to be demonstrated.
Outcomes on resistant bacteria were not assessed in this
study. Preliminary analysis shows an impact on the inci-
dence of infection due to C. difficile and the frequency of
vancomycin-resistant enterococci. A formal analysis using
ITS and a more appropriate modeling of possibly delayed
effects on nosocomial (versus community-acquired) in-
fection will be needed to fully understand the impact of
the programme on resistant bacteria. We are particularly
interested to measure effects over time on third-generation
cephalosporin-resistant enteric bacteria since there is a lack
of data allowing to assess the role if any of hospital-based
interventions on the epidemiology of this group of
microorganisms.
The investment needed for the programme was moder-
ate. The priorities of the existing infectious disease consult-
ant service were redefined, and, with some additional
personnel resources, the achievement of net cost savings
was very likely. Our estimate of net savings of almost
150,000 € for a 300-bed service (i.e. ~500 € per bed) is an
important finding but was derived from a simple before/
after analysis that cannot differentiate between truly
intervention-related savings and other effects. No attempt
was made to quantify other potential cost savings such as
shorter lengths of stay with better utilization of the in-
patient service, impact on antiviral and antifungal drug use,
or fewer infectious complications due to resistant bacteria
and C. difficile. Interestingly, recent experience from North
America indicate very similar initial net cost savings associ-
ated with an ABS programme if only antibacterial drugs
were assessed, and much higher cost savings when anti-
fungal drugs were included in the analysis [17].
Conclusion
In conclusion, an intensified ABS programme targeting
cephalosporin und fluoroquinolone use in the setting of a
large academic hospital is feasible and effective. Our inter-
vention may serve as a model for transferring this or simi-
lar programs to other services and to other hospitals with
similar structures and a similar baseline situation.
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